COVID-19 pandemic : What about the safety of anti-coronavirus nanoparticles?
Loading...
Access rights
openAccess
publishedVersion
URL
Journal Title
Journal ISSN
Volume Title
A2 Katsausartikkeli tieteellisessä aikakauslehdessä
This publication is imported from Aalto University research portal.
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
Other link related to publication (opens in new window)
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
Other link related to publication (opens in new window)
Date
2021-03
Major/Subject
Mcode
Degree programme
Language
en
Pages
24
Series
Nanomaterials, Volume 11, issue 3
Abstract
Every day, new information is presented with respect to how to best combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This manuscript sheds light on such recent findings, including new co-factors (i.e., neuropilin-1) and routes (i.e., olfactory transmucosal) allowing cell entry of SARS-CoV-2 and induction of neurological symptoms, as well as the new SARS-CoV-2 variants. We highlight the SARS-CoV-2 human–animal interfaces and elaborate containment strategies using the same vaccination (i.e., nanoparticle “NP” formulations of the BNT162b2 and mRNA-1273 vaccines) for humans, minks, raccoon dogs, cats, and zoo animals. We investigate the toxicity issues of anti-CoV NPs (i.e., plasmonic NPs and quantum dots) on different levels. Namely, nano–bio interfaces (i.e., protein corona), in vitro (i.e., lung cells) and in vivo (i.e., zebrafish embryos) assessments, and impacts on humans are discussed in a narrative supported by original figures. Ultimately, we express our skeptical opinion on the comprehensive administration of such antiviral nanotheranostics, even when integrated into facemasks, because of their reported toxicities and the different NP parameters (e.g., size, shape, surface charge, and purity and chemical composition of NPs) that govern their end toxicity. We believe that more toxicity studies should be performed and be presented, clarifying the odds of the safe administration of nanotoxocological solutions and the relief of a worried public.Description
Publisher Copyright: © 2021 by the author. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
Keywords
Human–animal interfaces, Lung cell lines, Nanoparticles, Nanotoxicology, SARS-CoV-2, Skeptical opinion, Zebrafish
Other note
Citation
Mosselhy, D A, Virtanen, J, Kant, R, He, W, Elbahri, M & Sironen, T 2021, ' COVID-19 pandemic : What about the safety of anti-coronavirus nanoparticles? ', Nanomaterials, vol. 11, no. 3, 796 . https://doi.org/10.3390/nano11030796